Hoechst Pakistan Limited’s September quarter was mixed rather than uniformly weak. Consolidated sales fell 5.6%, but cost of sales declined faster and gross margin improved to 38.0%. The benefit was absorbed by a much larger commercial and administrative cost base, a sharp rise in expected-credit-loss expense and higher finance costs. Quarterly profit consequently fell 29.0% to PKR 616 million. The nine-month result remained substantially ahead of last year, although a material first-half gain linked to the Sindh Infrastructure Development Cess settlement means that improvement should not be treated as entirely recurring.
Results at a glance
- Period and basis: unaudited consolidated results for the quarter and nine months ended September 30, 2026. The unconsolidated statements were checked as a reconciliation.
- Quarterly revenue: PKR 7.82 billion, down 5.6% from PKR 8.29 billion.
- Quarterly gross profit: PKR 2.97 billion, down 2.5%; gross margin improved to 38.0% from 36.8%.
- Quarterly operating profit: PKR 1.10 billion, down 28.9%; operating margin declined to 14.1% from 18.7%.
- Quarterly profit after tax: PKR 616 million, down 29.0%; EPS was PKR 63.87 versus PKR 89.96.
- Nine-month profit after tax: PKR 2.81 billion, up 27.0%, while revenue was nearly flat at PKR 24.53 billion.
- No new cash dividend, bonus issue or rights issue was announced with this result. The company had already declared an interim dividend of PKR 80 per share with its half-year result.
AlphaGen model readings
These are AlphaGen model outputs, not company-reported figures: Alpha QoQ Score 9.44; TTM Performance Score 70.12; 3Y Business Perf Score 93.49; Sector Leadership Score 21. They are comparative analytical indicators and are not investment advice.
What improved
The strongest operating feature was gross-margin resilience. Quarterly revenue declined by PKR 468 million, but cost of sales fell by PKR 390 million, or 7.5%. Gross profit therefore declined by only PKR 78 million, and gross margin increased by 1.21 percentage points to 38.0%. The result establishes that the cost base contracted faster than sales; it does not disclose whether this came from procurement, production efficiency, product mix, pricing or inventory effects.
The first-half report provides useful but earlier context. Management then attributed the improvement in gross margin to production and procurement efficiencies and a better sales mix across multiple product categories. Those factors may help explain the nine-month direction, but the September filing does not provide current-quarter volumes, product-level revenue or a gross-profit bridge. It would therefore be unsafe to assume the same drivers fully explain Q3.
The nine-month numbers show a much stronger cumulative picture. Revenue was almost unchanged at PKR 24.53 billion, but gross profit increased 10.5% to PKR 9.58 billion and gross margin rose to 39.1% from 35.3%. Operating profit increased 23.0% to PKR 4.86 billion, while profit after tax rose 27.0% to PKR 2.81 billion. EPS increased to PKR 291.07 from PKR 229.21.
Other expenses also moved favourably, declining 15.3% over nine months and 20.2% in the quarter. Short-term investments rose to PKR 2.35 billion from PKR 1.29 billion at December, while stock-in-trade declined 4.1% and trade debts fell 22.2%. These balance-sheet movements improved the company’s immediately available financial-asset position and reduced the amount tied up in inventory and customer balances.
What weakened / needs attention
The central Q3 weakness was the rise in operating expenses below gross profit. Distribution and marketing costs increased 32.4% to PKR 1.43 billion, while administrative expenses rose 36.5% to PKR 309 million. The filing does not describe the campaign, product-launch or organisational components of this increase. At the half-year stage, management had said promotional activity aligned with business requirements was lifting distribution expense. That statement gives context, but it does not establish how much of the Q3 increase is temporary or repeatable.
Allowance for expected credit loss increased to PKR 85 million from PKR 3 million in the comparable quarter. The absolute amount is smaller than distribution spending, but the change is material to the earnings bridge. Without the detailed quarterly notes, it is not possible to determine whether the charge arose from specific counterparties, an ageing shift or a revised probability assumption.
Other income increased to PKR 121 million from PKR 91 million in the quarter, but that uplift was far too small to offset the higher operating costs. Operating profit fell by PKR 447 million even though gross profit declined by only PKR 78 million. In other words, most of the profit contraction occurred after gross profit, not in manufacturing margin.
Finance costs rose to PKR 52.6 million from PKR 18.3 million in Q3. The balance sheet does not show conventional bank borrowing; the financing liabilities are principally lease obligations, alongside a separately recognised SIDC liability. The filing does not provide enough note detail to allocate the finance-cost increase precisely, so it should not be attributed to a particular instrument.
Tax did not change the direction of the result. Profit before income tax declined 31.5% to PKR 1.05 billion, while the tax charge fell 34.8% to PKR 431 million. The effective quarterly tax rate was about 41%, close to the comparable period. Net margin narrowed to 7.9% from 10.5%.
Why the nine-month result needs adjustment
Nine-month other income increased almost fivefold to PKR 985 million from PKR 199 million. The half-year report explained that the 2026 amendment to the Sindh Development and Maintenance of Infrastructure Cess framework led the company to recognise an overall gain of PKR 670 million in other income. The September cash-flow statement also shows reversals and remeasurement gains related to SIDC. These are reported earnings, but they are not equivalent to recurring pharmaceutical sales margin.
The contrast between periods is instructive. The first six months generated approximately PKR 2.19 billion of consolidated profit after tax, while Q3 added PKR 616 million. Nine-month profit growth therefore reflects both stronger first-half operations and the SIDC-related accounting benefit, whereas the September quarter itself shows slowing revenue and heavier commercial spending.
Balance sheet and liquidity
Consolidated current assets increased 7.9% from December to PKR 11.31 billion, while current liabilities rose 9.1% to PKR 6.67 billion. The current ratio was broadly stable at about 1.70 times versus 1.71 times. Excluding inventory, the quick ratio improved to roughly 0.74 times from 0.63 times because short-term investments increased and inventory declined.
Property, plant and equipment increased 26.8% to PKR 3.27 billion. The short-form announcement does not identify the projects behind that increase. Nine-month fixed capital expenditure was PKR 853 million, lower than PKR 1.37 billion in the comparable period. Investors should distinguish additions to productive capacity from lease-related or accounting movements when the detailed report becomes available.
Equity increased 2.5% to PKR 8.40 billion despite strong earnings because dividends absorbed a large part of the accumulated profit. The cash-flow statement records PKR 2.59 billion of dividends paid during the nine months, 68.7% more than a year earlier. The changes-in-equity statement reflects the PKR 190 final dividend for 2025 and the PKR 80 interim dividend for the first half of 2026.
Cash flow
Cash generated from operations declined 6.1% to PKR 5.98 billion, and net operating cash flow fell 17.4% to PKR 4.18 billion. Income-tax payments increased to PKR 1.49 billion, while SIDC payments of PKR 152 million and retirement-benefit payments of PKR 159 million also reduced operating cash.
After PKR 853 million of capital expenditure, operating cash less capital expenditure was approximately PKR 3.32 billion, compared with PKR 3.68 billion a year earlier. This is a cash-flow measure calculated from the filing, not a company-defined performance metric. It remained positive and covered the period’s dividend payments, although the cushion narrowed.
Net investing outflow fell to PKR 1.57 billion from PKR 2.31 billion, while net financing outflow was PKR 2.66 billion, largely dividends and lease rentals. Cash and cash equivalents ended at PKR 142 million, versus PKR 102 million a year earlier. The company also held PKR 2.35 billion in short-term investments, so bank cash alone understates its liquid financial assets.
Commercial partnership: opportunity with timing risk
Alongside the result, Hoechst Pakistan disclosed that it had obtained applicable legal and regulatory approvals for exclusive distribution in Pakistan of Tentan AG’s Dianatal Obstetric Gel. Commercialisation is expected in the first half of 2027. The partnership could broaden the product portfolio, but the filing gives no revenue target, margin expectation, launch cost or working-capital requirement. It should therefore be treated as an identifiable opportunity with unquantified economics rather than as a current earnings driver.
The group structure remains straightforward for this result. Consolidated Q3 revenue exceeded the parent-only figure by about PKR 31 million, and consolidated profit was only about PKR 1.6 million higher. Subsidiary activity therefore did not materially alter the quarterly verdict, although the detailed report may provide more information on H-Pack Wellness and the trading subsidiary.
Longer-run context
Reported annual revenue increased from about PKR 14.50 billion in 2019 to PKR 30.93 billion in 2025, a compound annual growth rate of roughly 13.5%. Over the same period, gross margin rose from 25.7% to 36.5% and net margin from 1.1% to 9.4%. The 2026 nine-month margin remains above the 2025 full-year level, but the Q3 profit decline shows that commercial-cost discipline is now as important as manufacturing margin.
What to monitor next
- The full September quarterly report, especially product-category sales, volumes, pricing, procurement savings and gross-margin notes.
- Whether distribution and marketing spending continues above 18% of sales, and whether it produces measurable revenue growth.
- The reason for the PKR 85 million expected-credit-loss charge and whether it reverses or recurs.
- Recurring operating profit after excluding the SIDC-related gain and other non-core income.
- Commercial launch milestones, costs and economics for Dianatal during the first half of 2027.
- Capital expenditure and the nature of the increase in property, plant and equipment.
- Operating cash conversion after nine-month cash flow weakened despite higher reported profit.
Evidence limitations
The official 13-page announcement verifies the exact reporting period, unaudited unconsolidated and consolidated earnings, balance sheet, changes in equity, cumulative cash flow and the new commercial partnership. It does not include explanatory notes, current product-level sales, volumes, pricing, utilisation, procurement detail or a reconciliation of the expected-credit-loss charge. The June report is used only for dated first-half context. Unsupported Q3 causal claims and discrete quarterly cash-flow conclusions have been omitted.
Primary sources
Pakistan Stock Exchange: Hoechst Pakistan Limited company and announcements page
Hoechst Pakistan Limited: half-year report for the period ended June 30, 2026
Hoechst Pakistan Limited: official financial reports archive